In short: In research literature, semaglutide is studied as a GLP-1 pathway agonist, retatrutide as a multi-receptor (GLP-1/GIP/glucagon) agonist, and tesamorelin as a growth-hormone-releasing-hormone analogue. They target different signalling systems and are handled as distinct research compounds.

Different pathways, different research questions

Semaglutide is examined in the GLP-1 receptor pathway. Retatrutide is studied as a triple-receptor agonist spanning GLP-1, GIP and glucagon signalling. Tesamorelin is a GHRH analogue investigated in the growth-hormone axis. Because their targets differ, they are not interchangeable in study design.

How researchers choose between them

Selection follows the research question and the receptor system under investigation, not potency alone. Each MyoLabs compound ships with batch documentation so results can be tied to a verified input: Retatrutide, Semaglutide, and Tesamorelin.

Frequently Asked Questions

What is the difference between retatrutide and semaglutide?

In research terms, semaglutide is studied at the GLP-1 receptor while retatrutide is studied as a multi-receptor agonist (GLP-1, GIP and glucagon). They engage different signalling pathways.

Is tesamorelin the same class as semaglutide?

No. Tesamorelin is a growth-hormone-releasing-hormone analogue, a different class from GLP-1 pathway compounds like semaglutide.

Which is best?

There is no single "best" — appropriateness depends entirely on the research pathway being studied. These are research compounds, not therapeutics.

Research Use Only. MyoLabs products are supplied strictly for laboratory and research use. They are not medicines and are not for human or animal consumption, diagnosis, treatment, or prevention of any condition. Always comply with the laws of your jurisdiction.